DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

BACKGROUND: There is an increasing interest for Notch signalling pathway and particularly Delta-like ligand 4 (DLL4) as potential therapeutic target to improve outcome for patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: Using immunohistochemistry (IHC) and tissue microarray (TMA), we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Drouillard, A, Puleo, F, Bachet, J B, Ouazzani, S, Calomme, A, Demetter, P, Verset, G, Van Laethem, J L, Maréchal, R
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Molecular Diagnostics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5104892/
https://ncbi.nlm.nih.gov/pubmed/27755532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.319
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados